Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000477635 | SCV000552052 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2025-01-01 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 701 of the PMS2 protein (p.His701Tyr). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This variant has not been reported in the literature in individuals affected with PMS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 411077). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is expected to disrupt PMS2 function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002418417 | SCV002725888 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2023-11-17 | criteria provided, single submitter | clinical testing | The p.H701Y variant (also known as c.2101C>T), located in coding exon 12 of the PMS2 gene, results from a C to T substitution at nucleotide position 2101. The histidine at codon 701 is replaced by tyrosine, an amino acid with similar properties. This alteration has been identified in a proband with MSI-H colorectal cancer and has also been identified as somatic in conjunction with copy neutral loss of heterozygosity (CN-LOH) in a MSI-H endometrial tumor with isolated loss of PMS2 protein expression by immunohistochemistry (IHC) (Ambry internal data). Based on internal structural analysis, this variant sits at the interface between PMS2/MutLa and is anticipated to result in a significant decrease in structural stability (Gueneau E et al. Nat Struct Mol Biol, 2013 Apr;20:461-8; Ambry internal data). Another alteration at the same codon, p.H701R (c.2102A>G), was also determined to be structurally destabilizing and was detected in a proband whose MSI-H colon cancer demonstrated isolated loss of PMS2 protein expression by IHC (Ambry internal data). Furthermore, the proband had a strong family history of HNPCC/Lynch syndrome-related cancers (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Baylor Genetics | RCV004568065 | SCV005056386 | uncertain significance | Lynch syndrome 4 | 2024-03-22 | criteria provided, single submitter | clinical testing |